Drug · DIN 02490331
VITRAKVI
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 4, 2019; first marketed September 4, 2019.
- Drug Identification Number (DIN)
- 02490331
- Company (DIN owner)
- Bayer Inc.Elkhart, Indiana, United States
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Oral
- Therapeutic class (ATC)
- Larotrectinib L01EX12
- Class
- Human
- Record last updated
- September 18, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LAROTRECTINIB (LAROTRECTINIB SULFATE) | 20 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 10, 2019: NOC 22387New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “vitrakvi”. A notice may cover another product or only some lots: read it to see what it covers.
- Vitrakvi: Presence of contamination in affected lotNovember 8, 2023 · Drugs · Contamination · Type II
Other DINs named VITRAKVI
- DIN 02490315 · Marketed
- DIN 02490323 · Marketed